20cm速递｜医药产业链催化不断，科创创新药ETF国泰（589720）近20日资金净流入近10亿元，资金积极布局

Group 1 - The pharmaceutical industry is experiencing continuous catalytic developments, with significant capital inflow into the Science and Technology Innovation Drug ETF (Guotai, 589720), which has seen nearly 1 billion yuan in net inflows over the past 20 days, indicating active capital positioning [1] - According to Zhongtai Securities, the raw material drug/intermediate industry has undergone 4-5 years of price decline, and with the rise in commodity and upstream chemical prices, a price improvement is expected. Most API product prices are at historical low levels, with limited profit margins and a low probability of further decline, showing a significant stabilization trend [1] - Innovative drug sectors such as small nucleic acids, peptides, and ADC toxins are continuously catalyzing the industry chain, contributing new business increments for raw material drug companies [1] Group 2 - The Science and Technology Innovation Drug ETF (Guotai, 589720) tracks the Science and Technology Innovation Drug Index (950161), which has a daily price fluctuation limit of 20%. This index focuses on new drug research and development driven by technological innovation, covering companies in the biopharmaceutical and chemical pharmaceutical sectors with high R&D investment and innovation capabilities, reflecting the overall trend of innovation development in China's pharmaceutical industry, with a focus on growth style in its allocation [1]